PRODUCT Properties
| Melting point: | 148-150°C |
| Boiling point: | 471.21°C (rough estimate) |
| Density | 1.1944 (rough estimate) |
| refractive index | 1.5700 (estimate) |
| storage temp. | Keep in dark place,Sealed in dry,Room Temperature |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| form | Solid |
| pka | 4.51±0.10(Predicted) |
| color | Crystals |
| CAS DataBase Reference | 6620-60-6(CAS DataBase Reference) |
| EPA Substance Registry System | Pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo- (6620-60-6) |
Description and Uses
Proglumide (Milid) is a drug that inhibits gastrointestinal motility and reduces gastric secretions. It acts as a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. It was used mainly in the treatment of stomach ulcers, although it has now been largely replaced by newer drugs for this application.
Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities.
Anticholinergic.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
| Toxicity | LD50 in mice (mg/kg): 2211-2649 i.v.; 7350-8861 orally (Rovati) |
